Drug intelligence / Profile preview

Aom-0304

Development stage: Phase 2
Lead developer: Aomo Pharma
Modality: Small Molecules

Overview

Aom-0304 is a small molecule drug under preclinical development by Hangzhou Adamerck Pharmlabs. Its primary therapeutic area is cardiovascular diseases, with a specific focus on hypertrophic cardiomyopathy. The precise mechanism of action and molecular targets have not been publicly disclosed as of the latest available update. The drug has not yet entered clinical trials or received regulatory approval.

Beyond the preview

Go deeper on Aom-0304.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aom-0304.

Explore the full profile